NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
21.76
-0.65 (-2.90%)
At close: Mar 28, 2025, 4:00 PM
20.86
-0.90 (-4.13%)
Pre-market: Mar 31, 2025, 7:40 AM EDT
Company Description
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V.
| Country | Netherlands |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Michael Davidson |
Contact Details
Address: Gooimeer 2-35 Naarden, 1411 DC Netherlands | |
| Phone | 31 35 206 2971 |
| Website | newamsterdampharma.com |
Stock Details
| Ticker Symbol | NAMS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001936258 |
| ISIN Number | NL00150012L7 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | Chief Executive Officer, President, Executive Board Member and Director |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board and Director |
| Mayur Amrat Somaiya | Chief Financial Officer |
| Douglas F. Kling | Chief Operating Officer |
| Juliette Audet M.B.A., M.Sc. | Chief Business Officer |
| Louise Kooij | Chief Accounting Officer |
| Matthew Philippe | Executive Vice President &Head of Investor Relations |
| Bob Rambo | Executive Vice President of Marketing |
| Maryellen McQuade | Chief People Officer |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2025 | 144 | Filing |
| Mar 26, 2025 | 144 | Filing |
| Mar 10, 2025 | EFFECT | Notice of Effectiveness |
| Mar 10, 2025 | 424B3 | Prospectus |
| Mar 4, 2025 | 144 | Filing |
| Feb 28, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 26, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |